Huons Lab and PanGen Biotech to develop denosumab biosimilar

INICIO/Noticias Farmacéuticas | Posted 30/04/2021 post-comment0 Post your comment

On 20 April 2021, Korean pharmaceutical company, Huons Lab, announced the development of a denosumab biosimilar to treat osteoporosis. The company is working with PanGen Biotech and using their cell line culturing and purification technology.

Shaking hands V13D29

The Huons Lab–PanGen Biotech agreement will take advantage of PanGen Biotech’s advanced technology to produce recombinant protein and develop process cell lines. Through this, Huons Lab hopes to rapidly develop the denosumab biosimilar to a stage where it can enter the Korean domestic and global markets.

Huons Lab has an existing agreement with Singapore-based Prestige BioPharma made in 2020 [1]. Here, Huons Lab has been granted exclusive Korean sales rights for HD204, an Avastin biosimilar, and PBP1502, a Humira biosimilar.

Amgen’s Prolia (denosumab) is the originator product with a patent ending in 2025. Denosumab is a humanized monoclonal antibody that is an inhibitor of the receptor activator of nuclear factor kappa-B ligand (RANKL). It works by preventing the development of osteoclasts that break down bone. It is used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumour of bone [2].

It has been estimated that the Prolia market grew to approximately US$5.13 billion worldwide in 2020. Cortellis, a healthcare research company, has estimated that the global Prolia market will expand 3.8 per cent annually until the patent expires. Huons and PanGen Biotech join a host of other pharmaceutical companies, in the development of denosumab biosimilars, these include Korea’s Samsung Bioepis [3], China’s Henlius [4], and Taiwan’s JHL Biotech [5].

Related articles
Korean biosimilars makers pipelines and expansion

Samsung Bioepis and Eden Biologics announce new biosimilar trials

Huons enters biosimilar market while private equity firm PAG invests in Hisum BioRay

PanGEn gains Malaysian approval for epoetin alfa biosimilar


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Aurobindo and Huons refocus their biologicals biosimilars portfolios []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 30]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of denosumab []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 30]. Available from: 
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilar advances for Samsung Bioepis []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 30]. Available from: 
4. GaBI Online - Generics and Biosimilars Initiative. China accepts IND application for denosumab copy biological HLX14 []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 30]. Available from: 
5. GaBI Online - Generics and Biosimilars Initiative. First subjects dosed in Australian phase I study of denosumab biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 30]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Licensing agreements signed for ustekinumab biosimilars
INICIO/Noticias Farmacéuticas Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
INICIO/Noticias Farmacéuticas Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
INICIO/Noticias Farmacéuticas Posted 03/09/2021
Teva signs deal with Bioeq for ranibizumab biosimilar FYB201
INICIO/Noticias Farmacéuticas Posted 30/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010